Peripheral Nervous System Manifestations of Infectious Diseases

The Neurohospitalist

Volumn 4, Issue 4, 2014, Pages 230-240

  Brizzi, Kate T ^a   Lyons, Jennifer L ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

antibiotics; antivirals; infectious disease; neuropathy; peripheral nervous system; radiculopathy

Indexed keywords

EID: 84992845448     PISSN: 19418744     EISSN: 19418752     Source Type: Journal    
DOI: 10.1177/1941874414535215     Document Type: Article

References (79)

1. Estanislao L Hart P Simpson D. HIV neuropathy and selected infectious neuropathies. Continuum. 2003; 9 (6): 118–145.
2. Kranick SM Nath A. Neurologic complications of HIV-1 infection and its treatment in the era of antiretroviral therapy. Contin Lifelong Learn Neurol. 2012; 18 (6): 1319–1337.
3. Abboud O Saliba I. Isolated bilateral facial paralysis revealing AIDS: a unique presentation. Laryngoscope. 2008; 118 (4): 580–584.
4. Lyons J Venna N Cho T. A typical nervous system manifestations of HIV. Semin Neurol. 2011; 31 (3): 254–265.
5. Goncalves DU Proietti FA Ribas JGR, et al. Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases. Clin Microbiol Rev. 2010; 23 (3): 577–589.
6. Araujo AQ Silva MTT. The HTLV-1 neurological complex. Lancet Neurol. 2006; 5 (12): 1068–1076.
7. Nascimento O Marques W. Human T-cell leukemia virus (HTLV)-associated neuropathy. Handb Clin Neurol. 2013; 115: 531–541.
8. Gabbai AA Wiley CA Oliveira AS, et al. Skeletal muscle involvement in tropical spastic paraparesis/HTLV-1-associated myelopathy. Muscle Nerve. 1994; 17 (8): 923–930.
9. Silva MTT Leite ACC Alamy AH Chimelli L Andrada-Serpa MJ Araujo AQC. ALS syndrome in HTLV-I infection. Neurology. 2005; 65 (8): 1332–1333.
10. Lalive PH Allali G Truffert A. Myasthenia gravis associated with HTLV-I infection and atypical brain lesions. Muscle Nerve. 2007; 35 (4): 525–528.
11. Cho T Vaitkevicius H. Infectious myelopathies. Contin Lifelong Learn Neurol. 2012; 18 (6): 1392–1416.
12. Steiner I. Herpes virus infection of the peripheral nervous system. Peripheral Nerve Disorders. 2013; 115: 543–558.
13. Elsberg CA. Experiences in spinal surgery: observation upon 60 laminectomies for spinal disease. Surg Gynecol Obstet. 1931; 16: 117–135.
14. Eberhardt O Kuker W Dichgans J Weller M. HSV-2 sacral radiculitis (Elsberg syndrome). Neurology. 2004; 63 (4): 758–759.
15. Ellie E Rozenberg F Dousset V Beylot-Barry M. Herpes simplex virus type 2 ascending myeloradiculitis: MRI findings and rapid diagnosis by the polymerase chain method. J Neurol Neurosurg Psychiatry. 1994; 57 (7): 869–870.
16. Krishna A Devulapally P Ghobrial I. Meningitis retention syndrome. J Community Hosp Intern Med Perspect. 2012; 2 (1): 1–3.
17. Aurelius E Forsgren M Gille E Skoldenberg B. Neurologic morbidity after herpes simplex type 2 meningitis: a retrospective study of 40 patients. Scand J Infect Dis. 2002; 34: 278–283.
18. Cresswell F Eadie J Longley N Macallan D. Severe Guillain–Barré syndrome following primary infection with varicella zoster virus in an adult. Int J Infect Dis. 2010; 14 (2): e161–e163.
19. Solomon CG Cohen JI. Herpes zoster. N Engl J Med. 2013; 369 (3): 255–263.
20. Orlikowski D Porcher R Sivadon-Tardy V, et al. Guillain-Barre syndrome following primary cytomegalovirus infection: a prospective cohort study. Clin Infect Dis. 2011; 52 (7): 837–844.
21. So YT Olney RK. Acute lumbosacral polyradiculopathy in acquired immunodeficiency syndrome: experience in 23 patients. Ann Neurol. 1994; 35 (1): 53–58.
22. Behar R Wiley C McCutchan J. Cytomegalovirus polyradiculoneuropathy in acquired immune deficiency syndrome. Neurology. 1987; 37 (4): 557–561.
23. Roullet E Assuerus V Gozlan J, et al. Cytomegalovirus multifocal neuropathy in AIDS analysis of 15 consecutive cases. Neurology. 1994; 44 (11): 2174–2174.
24. Kim Y Hollander H. Polyradiculopathy due to cytomegalovirus: report of two cases in which improvement occurred after prolonged therapy and review of the literature. Clin Infect Dis. 1993; 17 (1): 32–37.
25. Dowling PC Cook SD. Role of infection in Guillain-Barré syndrome: laboratory confirmation of herpes viruses in 41 cases. Ann Neurol. 1981; 9 (suppl): 44–55.
26. Majid A Galetta S Sweeney C, et al. Epstein-Barr virus myeloradiculitis and encephalomyeloradiculitis. Brain. 2002; 125 (pt 1): 159–165.
27. Lindsey NP Staples JE Lehman JA Fischer M. Surveillance for human west Nile virus disease—United States, 1999-2008. MMWR Surveill Summ. 2010; 59 (2): 1–17.
28. Petersen LR. West Nile virus: review of the literature. JAMA. 2013; 310 (3): 308–315.
29. Burton JM Kern RZ Halliday W, et al. Neurological manifestations of West Nile virus infection. Can J Neurol Sci. 2003; 31 (2): 185–193.
30. Monaco S Ferrari S Gajofatto A Zanusso G Mariotto S. HCV-related nervous system disorders. Clin Dev Immunol. 2012; 2012: 1–9.
31. Cacoub P Saadoun D Limal N Leger JM Maisonobe T. Hep C virus infection and mixed cryoglobulinaemia vasculitis: a review of neurological complications. AIDS. 2005; 19 (suppl 3): S128–S134.
32. Mayo MJ Kaplan NM Palmer BF. Extrahepatic manifestations of hepatitis C infection. Am J Med Sci. 2003; 325 (3): 135–148.
33. Nemni R Sanvito L Quattrini A Santuccio G Camerlingo M Canal N. Peripheral neuropathy in hepatitis C virus infection with and without cryoglobulinaemia. J Neurol Neurosurg Psychiatry. 2003; 74 (9): 1267–1271.
34. Bonetti B Scardoni M Monaco S Rizzuto N Scarpa A. Hepatitis C virus infection of peripheral nerves in type II cryoglobulinaemia. Virchows Arch. 1999; 434 (6): 533–535.
35. Briani C Chemello L Zara G, et al. Peripheral neurotoxicity of pegylated interferon alpha: a prospective study in patients with HCV. Neurology. 2006; 67 (5): 781–785.
36. Ammendola A Sampaolo S Ambrosone L, et al. Peripheral neuropathy in hepatitis-related mixed cryoglobulinemia: electrophysiologic follow-up study. Muscle Nerve. 2005; 31 (3): 382–385.
37. Jackson AC. Rabies. Neurol Clin. 2008; 26 (3): 717–726.
38. Hemachudha T Ugolini G Wacharapluesadee S Sungkarat W Shuangshoti S Laothamatas J. Human rabies: neuropathogenesis, diagnosis, and management. Lancet Neurol. 2013; 12 (5): 498–513.
39. Willoughby RE Jr Tieves KS Hoffman GM, et al. Survival after treatment of rabies with induction of coma. N Engl J Med. 2005; 352 (24): 2508–2514.
40. Stanek G Wormser GP Gray J Strle F. Lyme borreliosis. Lancet. 2012; 379 (9814): 461–473.
41. Gerber MA Shapiro ED Burke GS Parcells VJ Bell GL. Lyme disease in children in southeastern Connecticut. N Engl J Med. 1996; 335 (17): 1270–1274.
42. Steere A. Lyme disease. N Engl J Med. 1989; 321 (9): 586–596.
43. Halperin JJ. Lyme disease and the peripheral nervous system. Muscle Nerve. 2003; 28 (2): 133–143.
44. Clark J Carlson RD Sasaki CT Pachner AR Steere AC. Facial paralysis in Lyme disease. Laryngoscope. 1985; 95 (11): 1341–1345.
45. Halperin J. Lyme neuroborreliosis. Peripheral nervous system manifestations. Brain. 1990; 113 (4): 1207–1221.
46. Bremell D Hagberg L. Clinical characteristics and cerebrospinal fluid parameters in patients with peripheral facial palsy caused by Lyme neuroborreliosis compared with facial palsy of unknown origin (Bell's palsy). BMC Infect Dis. 2011; 11(1):1–6.
47. Pfister HW Einhäupl K Preac-Mursic V Wilske B Schierz G. The spirochetal etiology of lymphocytic meningoradiculitis of Bannwarth (Bannwarth's syndrome). J Neurol. 1984; 231 (3): 141–144.
48. Eppes SC Nelson DK Lewis LL Klein JD. Characterization of Lyme meningitis and comparison with viral meningitis in children. Pediatrics. 1999; 103 (5): 957–960.
49. Tuerlinckx D Bodart E Jamart J Glupczynski Y. Prediction of Lyme meningitis based on a logistic regression model using clinical and cerebrospinal fluid analysis: a European study. Pediatr Infect Dis J. 2009; 28 (5): 394–397.
50. Shah SS Zaoutis TE Turnquist J Hodinka RL Coffin SE. Early differentiation of Lyme from enteroviral meningitis. Pediatr Infect Dis J. 2005; 24 (6): 542–545.
51. Nadelman RB Hanincová K Mukherjee P, et al. Differentiation of reinfection from relapse in recurrent Lyme disease. N Engl J Med. 2012; 367 (20): 1883–1890.
52. Wormser GP Dattwyler RJ Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the infectious diseases society of America. Clin Infect Dis. 2006; 43 (9): 1089–1134.
53. Nyati KK Nyati R. Role of Campylobacter jejuni infection in the pathogenesis of Guillain-Barré syndrome: an update. Biomed Res Int. 2013; 2013: 1–13.
54. Rees JH Soudain SE Gregson NA Hughes RA. Campylobacter jejuni infection and Guillain–Barré syndrome. N Engl J Med. 1995; 333 (21): 1374–1379.
55. Mishu B Ilyas AA Koski CL, et al. Serologic evidence of previous Campylobacter jejuni infection in patients with the Guillain-Barré syndrome. Ann Intern Med. 1993; 118 (12): 947–953.
56. Van Doorn PA Ruts L Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol. 2008; 7 (10): 939–950.
57. Hughes RA Swan AV van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. In: The Cochrane Collaboration, Hughes RA, eds. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2012; 7.
58. Hadfield TL McEvoy P Polotsky Y Tzinserling VA Yakovlev AA. The pathology of diphtheria. J Infect Dis. 2000; 181 (suppl 1): S116–S120.
59. Cléange A Meyrignac C Roualdes B Degos JD Gherardi RK. Diphtheritic neuropathy. Muscle Nerve. 1995; 18 (12): 1460–1463.
60. Gul HC Erdem H Bek S. Overview of neurobrucellosis: a pooled analysis of 187 cases. Int J Infect Dis. 2009; 13 (6): e339–e343.
61. Guven T Ugurlu K Ergonul O, et al. Neurobrucellosis: clinical and diagnostic features. Clin Infect Dis. 2013; 56 (10): 1407–1412.
62. Shapiro RL Hatheway C Swerdlow DL. Botulism in the United States: a clinical and epidemiologic review. Ann Intern Med. 1998; 129 (3): 221–228.
63. Sobel J. Botulism. Clin Infect Dis. 2005; 41 (8): 1167–1173.
64. Dye C. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. JAMA. 1999; 282 (7): 677–686.
65. Phypers M Harris T Power C. CNS tuberculosis: a longitudinal analysis of epidemiological and clinical features. Int J Tuberc Lung Dis. 2006; 10 (1): 99–103.
66. Sharma P Garg RK Verma R Singh MK Shukla R. Incidence, predictors and prognostic value of cranial nerve involvement in patients with tuberculous meningitis: a retrospective evaluation. Eur J Intern Med. 2011; 22 (3): 289–295.
67. Le Page L Feydy A Rillardon L, et al. Spinal tuberculosis: a longitudinal study with clinical, laboratory, and imaging outcomes. Semin Arthritis Rheum. 2006; 36 (2): 124–129.
68. Thwaites GE Hien TT. Tuberculous meningitis: many questions, too few answers. Lancet Neurol. 2005; 4 (3): 160–170.
69. Rodrigues LC Lockwood DN. Leprosy now: epidemiology, progress, challenges, and research gaps. Lancet Infect Dis. 2011; 11 (6): 464–470.
70. Ooi W Shrinivasan J. Leprosy and the peripheral nervous system. Muscle Nerve. 2004; 30 (4): 393–409.
71. Agrawal A Pandit L Dalal M Shetty JP. Neurological manifestations of Hansen's disease and their management. Clin Neurol Neurosurg. 2005; 107 (6): 445–454.
72. Britton WJ Lockwood D. Leprosy. Lancet. 2004; 363 (9416): 1209–1219.
73. Wagenaar I Brandsma W Post E, et al. Two randomized controlled clinical trials to study the effectiveness of prednisolone treatment in preventing and restoring clinical nerve function loss in leprosy: the TENLEP study protocols. BMC Neurol. 2012; 12 (1): 159.
74. Rassi A Rassi A Marcondes de Rezende J. American trypanosomiasis (Chagas disease). Infect Dis Clin North Am. 2012; 26 (2): 275–291.
75. Genovese O Ballario C Storino R Segura E Sica RE. Clinical manifestations of peripheral nervous system involvement in human chronic Chagas disease. Arq Neuropsiquiatr. 1996; 54 (2): 190–196.
76. Goin JC Venera G Bonino M Sterin-Borda L. Circulating antibodies against nicotinic acetylcholine receptors in chagasic patients. Clin Exp Immunol. 1997; 110 (2): 219–225.
77. Kuehn B. FDA warning and study highlight fluoroquinolone risks. JAMA. 2013; 310 (10): 1014.
78. Kass JS Shandera WX. Nervous system effects of antituberculosis therapy. CNS Drugs. 2010; 24 (8): 655–667.
79. Rho J Sia I Crum B Dekutoski M Trousdale R. Linezolid-associated peripheral neuropathy. Mayo Clin Proc. 2004; 79 (7): 927–930.